# US 2023/0405315 A1 · Compositions And Methods For Treating With A Combination Of Alternating Electric Fields And FGF Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405315 A1
- Document ID: US20230405315A1
- Status: Published application
- Kind: A1
- Application number: 18/336,880
- Filed: 2023-06-16
- Published: 2023-12-21
- Earliest claimed: 2022-06-18
- Applicants: Novocure GmbH
- Inventors: Tali Voloshin-Sela; Lilach Avigdor; Anat Klein-Goldberg; Rom Paz; Elizabeth Moyal; Valerie Gouaze Andersson
- Web page: https://patentgrep.com/patent/US20230405315A1

## CPC

- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61N 1/36002: {Cancer treatment, e.g. tumour}
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61N 1/40: Applying electric fields by inductive or capacitive coupling (microwave apparatus A61N5/00); {Applying radio-frequency signals}
- A61P 35/00: Antineoplastic agents
- A61N 1/06: for high-frequency therapy
- A61N 1/36034: {specified by the stimulation parameters}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods of treating a subject in need thereof comprising: applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and administering one or more FGF inhibitors or FGFR inhibitors to the subject in need thereof. Disclosed are methods of increasing a cell's sensitivity to alternating electric fields comprising: applying alternating electric fields, at a frequency for a period of time, to a cell; and contacting one or more FGF inhibitors or FGFR inhibitors to the cell, thereby increasing the cell's sensitivity to the alternating electric fields. Disclosed are methods of increasing cytotoxicity in a cell comprising: applying alternating electric fields, at a frequency for a period of time, to a cell; and contacting one or more FGF inhibitors or FGFR inhibitors to the cell, thereby increasing cytotoxicity in the cell. Disclosed are methods of maintaining, or enhancing, sensitivity to alternating electrical fields in a cell comprising: applying alternating electric fields, at a frequency for a period of time, to a cell; and contacting one or more FGF inhibitors or FGFR inhibitors to the cell, thereby maintaining, or enhancing, sensitivity to the alternating electrical fields in the cell. In some aspects, maintaining, or enhancing, sensitivity of a cell to alternating electrical fields is the same as reducing resistance of the cell to alternating electrical fields.

## Claims

### Claim 1

A method of treating a subject in need thereof comprising:
a) applying alternating electric fields, at a frequency for a period of time, to a target site of the subject in need thereof; and
b) administering one or more fibroblast growth factor (FGF) inhibitors or fibroblast growth factor receptor (FGFR) inhibitors to the subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has mesothelioma, ovarian cancer or lung cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the target site comprises one or more cancer cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the alternating electric fields are applied before, after, or simultaneously with administering the one or more FGF or FGFR inhibitors.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more FGF or FGFR inhibitors are administered intratumorally, intracranially, intraventricularly, intrathecally, epidurally, intradurally, intravascularly, intravenously (targeted or non-targeted), intraarterially, intramuscularly, subcutaneously, intraperitoneally, orally, intranasally, via intratumor injection (e.g. computed tomography-guided, during surgery or biopsy) or via inhalation.

### Claim 6

A method of increasing a cell's sensitivity to alternating electric fields comprising:
a) applying alternating electric fields, at a frequency for a period of time, to a cell; and
b) contacting one or more fibroblast growth factor (FGF) inhibitors or a fibroblast growth factor receptor (FGFR) inhibitors to the cell,
thereby increasing the cell's sensitivity to the alternating electric fields.

### Claim 7

A method of increasing cytotoxicity in a cell comprising:
a) applying alternating electric fields, at a frequency for a period of time, to a cell; and
b) contacting one or more fibroblast growth factor (FGF) inhibitors or a fibroblast growth factor receptor (FGFR) inhibitors to the cell,
thereby increasing cytotoxicity in the cell.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cell is in vitro or in a subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein the FGF inhibitor inhibits or decreases FGF expression.

### Claim 10 (depends on 1)

The method of claim 1, wherein the FGF inhibitor blocks upregulation of FGF expression in response to alternating electric fields.

### Claim 11 (depends on 1)

The method of claim 1, wherein the FGF inhibitor prevents FGF from interacting or binding to one or more FGF receptors (FGFR).

### Claim 12 (depends on 1)

The method of claim 1, wherein the FGFR inhibitor prevents FGFR from interacting or binding with one or more FGFs.

### Claim 13 (depends on 1)

The method of claim 1, wherein the FGFR inhibitor blocks one or more FGF receptors (FGFR).

### Claim 14 (depends on 1)

The method of claim 1, wherein the FGF is FGF-21, FGF-19, FGF-7, FGF-basic.

### Claim 15 (depends on 1)

The method of claim 1, wherein the FGFR is FGFR1, FGFR2, FGFR3, or FGFR4.

### Claim 16 (depends on 1)

The method of claim 1, wherein the FGFR inhibitor can be one or more of the inhibitors of Table 1.

### Claim 17 (depends on 6)

The method of claim 6, wherein the cancer cell is an ovarian cancer or lung cancer cell.

### Claim 18 (depends on 1)

The method of claim 1, wherein the frequency of the alternating electric field is between 50 kHz and 1 MHz.

### Claim 19 (depends on 1)

The method of claim 1, wherein the alternating electric field has a field strength of between 0.5 and 4 V/cm RMS.

### Claim 20 (depends on 1)

The method of claim 1, further comprising administering a cancer therapeutic.
